Company intelligence / Profile preview

Genomas

Hartford, Connecticut, United Statestandfonline.com ↗

Ownership: Private
Development stage: Commercial

Overview

Genomas developed and commercialized DNA-guided diagnostic systems to help physicians personalize drug prescriptions—especially for statins and antipsychotics—by predicting patient-specific risk for adverse side effects based on genetic polymorphisms. Their PhyzioType® technology was used in clinical practice via their Laboratory of Personalized Health.

Therapeutic areas: PsychiatryCardiovascularEndocrinologyNeurology
Modalities: Genetic testingDNA-guided diagnostics
Industry: Molecular Diagnostics

Partnerships

Hartford Hospital (seed investment, clinical collaboration)AutoGenomics Inc. (strategic partnership to co-develop DNA-guided diagnostic systems for statins)

Beyond the preview

Go deeper on Genomas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genomas.

Explore the full profile